Cannalean Biotechs

Company Overview

Snapshot

Founded in March 2018 by David Bassa, Cannalean Biotechs operates with 1–10 employees. The company is focused on the research and development of CBD-based solutions. In January 2026, Cannalean Biotechs announced the positive completion of a first-in-human feasibility study for its novel CBD-based lipid-lowering therapy.

Business overview

Cannalean Biotechs is a Health Tech & Life Sciences company committed to the research and development of proprietary cannabidiol (CBD) and chitosan formulations. The company's core technology involves a synthetic form of CBD combined with chitosan, a biocompatible compound, designed to enhance CBD's potential to reduce lipid blood levels. Cannalean Biotechs focuses on developing treatments for dyslipidemia, serving the pharmaceutical and healthcare industries, with a primary target market of patients.

Strategic signal

In January 2026, Cannalean Biotechs announced the positive completion of its first-in-human feasibility study for a novel CBD-based lipid-lowering therapy. This milestone is significant as it validates the initial safety and potential efficacy of their proprietary formulation, signaling to investors and the industry a crucial step forward in the clinical development of a new treatment alternative for dyslipidemia.

Company Intelligence Q&A

What is Cannalean Biotechs' primary focus?

Cannalean Biotechs is committed to the research and development of a proprietary formulation of cannabidiol (CBD) and chitosan for treating dyslipidemia.

When did Cannalean Biotechs announce the positive completion of its first-in-human feasibility study?

In January 2026, Cannalean Biotechs announced the positive completion of a first-in-human feasibility study for its novel CBD-based lipid-lowering therapy.

What is the core technology behind Cannalean Biotechs' formulation?

Cannalean Biotechs utilizes a synthetic form of CBD combined with chitosan, a biocompatible compound, to enhance the potential of CBD in reducing lipid blood levels.

When did Cannalean Biotechs announce a Phase 2a clinical trial?

In June 2022, Cannalean Biotechs announced a Phase 2a clinical trial for its cannabidiol-based formulation aimed at lowering blood cholesterol levels.

When was Cannalean Biotechs founded?

Cannalean Biotechs was founded in March 2018.